Aberdeen Group plc Increases Stake in Janux Therapeutics, Inc. $JANX

Aberdeen Group plc boosted its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 21.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 345,476 shares of the company’s stock after buying an additional 60,188 shares during the quarter. Aberdeen Group plc’s holdings in Janux Therapeutics were worth $8,443,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the company. California State Teachers Retirement System raised its stake in Janux Therapeutics by 1.1% in the 2nd quarter. California State Teachers Retirement System now owns 37,139 shares of the company’s stock worth $858,000 after acquiring an additional 404 shares during the last quarter. ProShare Advisors LLC lifted its position in shares of Janux Therapeutics by 8.1% in the second quarter. ProShare Advisors LLC now owns 10,284 shares of the company’s stock valued at $238,000 after acquiring an additional 771 shares in the last quarter. Ameritas Investment Partners Inc. grew its holdings in shares of Janux Therapeutics by 25.6% during the second quarter. Ameritas Investment Partners Inc. now owns 4,020 shares of the company’s stock worth $93,000 after buying an additional 820 shares in the last quarter. Virtus Investment Advisers LLC lifted its stake in Janux Therapeutics by 37.9% in the 2nd quarter. Virtus Investment Advisers LLC now owns 3,679 shares of the company’s stock worth $85,000 after purchasing an additional 1,011 shares in the last quarter. Finally, DNB Asset Management AS increased its stake in shares of Janux Therapeutics by 19.2% in the 2nd quarter. DNB Asset Management AS now owns 9,253 shares of the company’s stock worth $214,000 after acquiring an additional 1,488 shares during the last quarter. Institutional investors own 75.39% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Wall Street Zen upgraded Janux Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Cantor Fitzgerald lowered their price target on Janux Therapeutics from $200.00 to $150.00 and set an “overweight” rating for the company in a report on Tuesday, December 2nd. HC Wainwright lowered their target price on shares of Janux Therapeutics from $70.00 to $45.00 and set a “buy” rating on the stock in a research report on Tuesday, December 2nd. Piper Sandler lowered their price objective on Janux Therapeutics from $42.00 to $30.00 and set an “overweight” rating on the stock in a report on Friday, January 16th. Finally, Wolfe Research began coverage on Janux Therapeutics in a report on Tuesday, November 18th. They issued a “peer perform” rating on the stock. Eleven equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $60.08.

Janux Therapeutics Price Performance

Shares of NASDAQ:JANX opened at $13.08 on Friday. Janux Therapeutics, Inc. has a 12 month low of $12.12 and a 12 month high of $38.42. The business has a 50-day moving average of $13.80 and a two-hundred day moving average of $21.08. The firm has a market capitalization of $786.76 million, a PE ratio of -7.79 and a beta of 2.88.

Insider Buying and Selling

In other Janux Therapeutics news, insider Zachariah Mciver sold 2,714 shares of the business’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $13.73, for a total transaction of $37,263.22. Following the transaction, the insider owned 23,286 shares in the company, valued at $319,716.78. The trade was a 10.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Andrew Hollman Meyer sold 3,333 shares of the stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $32.98, for a total transaction of $109,922.34. Following the completion of the sale, the insider directly owned 84,974 shares of the company’s stock, valued at $2,802,442.52. This trade represents a 3.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 22,366 shares of company stock valued at $371,245 over the last ninety days. Insiders own 8.10% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.